Last Update 16 Feb 26

Fair value Increased 11%

MDGL: Future Leadership Will Rely On MASH Cirrhosis Uptake Versus GLP 1 Pressure

The analyst price target for Madrigal Pharmaceuticals has been revised higher to $671.07, up from $603.47. Analysts now factor in updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E, following recent research that highlights both enthusiasm for Rezdiffra's commercial potential and some valuation concerns.

Analyst Commentary

Recent research on Madrigal Pharmaceuticals shows a split view, with some analysts focusing on upside linked to Rezdiffra and pipeline optionality, while others highlight valuation and competitive risks. Here is how those views break down.

Bullish Takeaways

Bullish analysts are raising price targets into the mid to high US$600 range, tying their views to updated models that factor in Rezdiffra's commercial potential in F2/F3 and MASH F4 subtypes.
Several reports reference increasing confidence in Rezdiffra as a liver directed oral backbone therapy, with potential for broader use if future F4c data are supportive. This feeds directly into their long term revenue and margin assumptions.
Some analysts emphasize feedback from key opinion leaders who report what they describe as robust real world uptake in high volume centers. They see this as supportive of their penetration assumptions and longer term growth scenarios.
The licensing of ervogastat from Pfizer, with a US$50m upfront payment plus potential milestones and royalties, is viewed by bullish analysts as adding combination therapy optionality in MASH. They incorporate this into future growth and pipeline valuation work.

Bearish Takeaways

Bearish analysts question whether the current share price already reflects optimistic peak sales scenarios. They suggest that even on higher buyside peak sales expectations around US$4b to US$6b, the stock may be trading at what they describe as a very full valuation.
One research group removes its prior explicit price target and moves to a more neutral stance. The group indicates less conviction that additional upside is justified purely on valuation given recent share price strength.
There are concerns that competition, including weight loss drugs, could pressure Rezdiffra's long term penetration and pricing. This introduces execution risk around the most optimistic revenue and earnings frameworks.
Some commentary points to patent strength around related assets as a weak spot. This could affect longer dated exclusivity assumptions and therefore the durability of cash flows that are embedded in more aggressive valuation models.

What's in the News

Madrigal Pharmaceuticals announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor in clinical development for MASH combination regimens, reinforcing its focus on liver disease therapies (Key Developments).
Ervogastat targets the final step in triglyceride assembly and storage, which is described as leading to lower hepatic triglycerides, reduced lipotoxic fat and decreased liver inflammation, a profile that may be relevant for future MASH combination approaches (Key Developments).
The company plans to share additional information on the ervogastat agreement and MASH pipeline plans at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 1:30 p.m. PST (Key Developments).

Valuation Changes

Fair Value: revised to $671.07 from $603.47, indicating a higher modeled equity value per share.
Discount Rate: adjusted slightly higher to 7.08% from 7.06%, reflecting a modest change in the risk or return assumptions used in the model.
Revenue Growth: updated to 54.66% from 54.88%, a small reduction in projected top line expansion in the forecast period.
Net Profit Margin: reset to 29.70% from 31.99%, implying a lower steady state profitability assumption in the earnings model.
Future P/E: increased to 24.30x from 20.19x, pointing to a higher valuation multiple applied to projected earnings.

41 views

Key Takeaways

Decades of patent protection and growing disease prevalence position Rezdiffra for sustained revenue growth, market expansion, and pricing power.
International launches, pipeline diversification, and solid financial resources reduce risk and support expansion into new markets and indications.
Dependence on a single drug, rising competition, reimbursement challenges, expansion risks, and escalating costs threaten Madrigal's margins, growth prospects, and earnings stability.

Catalysts

About Madrigal Pharmaceuticals

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.What are the underlying business or industry changes driving this perspective?

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.
The increasing global prevalence of advanced metabolic and liver diseases, driven by aging populations and lifestyle trends, is expanding the addressable market for Rezdiffra; the company's early-stage penetration (7% of diagnosed U.S. MASH patients) leaves significant room for future patient growth and recurring revenues.
Upcoming international expansion, beginning with the imminent launch in Germany and broader EU approval, positions the company to tap into new, underpenetrated markets with a sizeable diagnosed MASH population and limited competition, driving incremental revenue growth.
Pipeline development, including the combination of Rezdiffra with a newly in-licensed oral GLP-1 agent, leverages advances in targeted metabolic therapies and positions Madrigal for future indication expansion and combination treatment adoption-supporting long-term revenue diversification and lifecycle management.
The company's strong cash reserves and favorable non-dilutive financing provide ample resources for business development, clinical advancement, and scaling operations, reducing financial risk and supporting investment in initiatives likely to boost future net income and earnings stability.

Madrigal Pharmaceuticals Earnings and Revenue Growth

Madrigal Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Madrigal Pharmaceuticals's revenue will grow by 68.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -54.7% today to 33.3% in 3 years time.
Analysts expect earnings to reach $822.9 million (and earnings per share of $31.0) by about September 2028, up from $-281.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.1 billion in earnings, and the most bearish expecting $291.0 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 15.7x on those 2028 earnings, up from -34.4x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 2.19% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Madrigal Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Heavy reliance on a single lead asset (Rezdiffra/resmetirom) exposes Madrigal to substantial risk if future clinical data (e.g., in F4c population) disappoint or if unforeseen safety/efficacy issues emerge, potentially resulting in significant revenue and earnings volatility.
Intensifying competition-including upcoming launches of GLP-1 class drugs and pipeline therapies from large-cap pharma-could erode Madrigal's first-mover advantage, put downward pressure on market share, and force pricing or rebating concessions, impacting both top-line growth and net margins.
Continued healthcare cost containment and reimbursement scrutiny-especially as payer contracting ramps up in the second half of 2025 and beyond-may drive gross to net discounts higher over time, limiting long-term pricing power and compressing future gross and net margins.
International expansion carries operational and reimbursement risks, especially in complex European markets where access, pricing, and adoption curves may be slower or flatter than in the U.S., delaying or diminishing expected revenue contributions from ex-U.S. launches.
High and rising SG&A and R&D expenses-particularly as Madrigal builds its pipeline and business development ambitions-could pressure operating margins and require further external financing, raising the risk of future shareholder dilution or elevated interest expense, negatively affecting long-term earnings per share.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $461.429 for Madrigal Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $567.0, and the most bearish reporting a price target of just $266.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $2.5 billion, earnings will come to $822.9 million, and it would be trading on a PE ratio of 15.7x, assuming you use a discount rate of 6.8%.
Given the current share price of $435.27, the analyst price target of $461.43 is 5.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Madrigal Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

EU Expansion and Combination Therapies Will Drive Future Opportunity